Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic.
Expert Rev Vaccines
; : 1-16, 2022 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2245349
ABSTRACT
INTRODUCTION:
COVID-19 vaccines have been highly effective in reducing morbidity and mortality during the pandemic. However, the emergence of the Omicron variant and subvariants as the globally dominant strains have raised doubts about the effectiveness of currently available vaccines and prompted debate about potential future vaccination strategies. AREAS COVERED Using the publicly available IVAC VIEW-hub platform, we reviewed 52 studies on vaccine effectiveness (VE) after booster vaccinations. VE were reported for SARS-CoV-2 symptomatic infection, severe disease and death and stratified by vaccine schedule and age. In addition, a non-systematic literature review of safety was performed to identify single or multi-country studies investigating adverse event rates for at least two of the currently available COVID-19 vaccines. EXPERT OPINION Booster shots of the current COVID-19 vaccines provide consistently high protection against Omicron-related severe disease and death. Additionally, this protection appears to be conserved for at least 3 months, with a small but significant waning after that. The positive risk-benefit ratio of these vaccines is well established, giving us confidence to administer additional doses as required. Future vaccination strategies will likely include a combination of schedules based on risk profile, as overly frequent boosting may be neither beneficial nor sustainable for the general population.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Tipo de estudio:
Estudio experimental
/
Estudio pronóstico
/
Revisiones
/
Revisión sistemática/Meta análisis
Tópicos:
Vacunas
/
Variantes
Idioma:
Inglés
Revista:
Expert Rev Vaccines
Asunto de la revista:
Alergia e Inmunología
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
14760584.2023.2143347
Similares
MEDLINE
...
LILACS
LIS